David A. Siegel Verve Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 381,300 shares of VERV stock, worth $4.24 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
381,300
Previous 173,800
119.39%
Holding current value
$4.24 Million
Previous $794,000
439.17%
% of portfolio
0.01%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding VERV
# of Institutions
189Shares Held
72.1MCall Options Held
452KPut Options Held
2.96M-
Alphabet Inc. Mountain View, CA12.2MShares$135 Million8.86% of portfolio
-
Pentwater Capital Management LP Naples, FL6.72MShares$74.8 Million0.5% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.19MShares$46.7 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4.1MShares$45.6 Million6.45% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $667M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...